Posted by Michael Wonder on 31 Oct 2019
Schedule of Pharmaceutical Benefits - 1 November 2019 update
1 November 2019 - The November 2019 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The November issue of the Schedule includes several new listings:
- Dabrafenib mesylate (Tafinlar) - new indication
- Fingolimod hydrochloride (Gilenya) - new indication
- Infliximab (Inflectra) - restriction change
- Mupirocin calcium (Mupirocin Nasal) - new formulation
- Naloxone hydrochloride (Nyxoid) - new formulation
- Trametinib dimethyl sulphoxide (Mekinist) - new indication
- Trastuzumab (Herzuma) - new biosimilar medicine
